Fizza Arain1,2,3, Lars Gullestad1,3,4, Ståle Nymo2, John Kjekshus1,3,4, John G Cleland5, Annika Michelsen2, John J McMurray6, John Wikstrand7, Pål Aukrust2,4,7,8,9, Thor Ueland2,4,8,10. 1. a Department of Cardiology , Oslo University Hospital Rikshospitalet , Oslo , Norway. 2. b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway. 3. c K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research , University of Oslo , Oslo , Norway. 4. d Faculty of Medicine , University of Oslo , Oslo , Norway. 5. e Department of Cardiology , Hull York Medical School, University of Hull, Castle Hill Hospital , Kingston-upon-Hull, Glasgow , UK. 6. f British Heart Foundation Glasgow Cardiovascular Research Centre , University of Glasgow , Glasgow , UK. 7. g Sahlgrenska University Hospital , Gøteborg , Sweden. 8. h K.G. Jebsen Inflammatory Research Center , University of Oslo , Oslo , Norway. 9. i Section of Clinical Immunology and Infectious Diseases , Oslo University Hospital Rikshospitalet Oslo , Norway. 10. j K.G. Jebsen Thrombosis Research and Expertise Center , University of Tromsø , Tromsø , Norway.
Abstract
CONTEXT AND OBJECTIVE: To evaluate if YKL-40 can provide prognostic information in patients with ischemic heart failure (HF) and identify patients who may benefit from statin therapy. MATERIALS AND METHODS: The association between serum YKL-40 and predefined outcome was evaluated in 1344 HF patients assigned torosuvastatin or placebo. RESULTS:YKL-40 was not associated with outcome in adjusted analysis. In YKL-40 tertile 1, an effect on the primary outcome (HR 0.50, p = 0.006) and CV death (HR 0.54, p = 0.040) was seen by rosuvastatin in adjusted analysis. CONCLUSIONS: A beneficial modification of outcome was observed with statin therapy in patients with low YKL-40 levels.
RCT Entities:
CONTEXT AND OBJECTIVE: To evaluate if YKL-40 can provide prognostic information in patients with ischemic heart failure (HF) and identify patients who may benefit from statin therapy. MATERIALS AND METHODS: The association between serum YKL-40 and predefined outcome was evaluated in 1344 HF patients assigned to rosuvastatin or placebo. RESULTS:YKL-40 was not associated with outcome in adjusted analysis. In YKL-40 tertile 1, an effect on the primary outcome (HR 0.50, p = 0.006) and CV death (HR 0.54, p = 0.040) was seen by rosuvastatin in adjusted analysis. CONCLUSIONS: A beneficial modification of outcome was observed with statin therapy in patients with low YKL-40 levels.
Authors: Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani Journal: Cochrane Database Syst Rev Date: 2020-02-27
Authors: Elke Bouwens; Victor J van den Berg; K Martijn Akkerhuis; Sara J Baart; Kadir Caliskan; Jasper J Brugts; Henk Mouthaan; Jan van Ramshorst; Tjeerd Germans; Victor A W M Umans; Eric Boersma; Isabella Kardys Journal: J Clin Med Date: 2020-01-10 Impact factor: 4.241